07:17 AM EDT, 10/30/2024 (MT Newswires) -- Biogen (BIIB) reported Q3 adjusted earnings Wednesday of $4.08 per diluted share, down from $4.36 a year earlier.

Analysts polled by Capital IQ expected $3.79.

Revenue for the quarter ended Sept. 30 was $2.47 billion, down from $2.53 billion a year earlier.

Analysts polled by Capital IQ expected $2.43 billion.

The company now expects 2024 adjusted diluted EPS of $16.10 to $16.60, up from its prior guidance of $15.75 to $16.25. Analysts surveyed by Capital IQ are expecting $16.18.

Price: 187.50, Change: +4.03, Percent Change: +2.20